1616809-39-2

Basic information

• Product Name: 3-((3,4-difluorophenyl)carbamoyl)-4-fluorobenzene-1-sulfonyl chloride
• Synonyms: 3-((3,4-difluorophenyl)carbamoyl)-4-fluorobenzene-1-sulfonyl chloride
• CAS NO: 1616809-39-2
• Molecular Weight: 349.718
• Mol File: 1616809-39-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3-((3,4-difluorophenyl)carbamoyl)-4-fluorobenzene-1-sulfonyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 3-((3,4-difluorophenyl)carbamoyl)-4-fluorobenzene-1-sulfonyl chloride(1616809-39-2)
• EPA Substance Registry System: 3-((3,4-difluorophenyl)carbamoyl)-4-fluorobenzene-1-sulfonyl chloride(1616809-39-2)

Safety Data

• Hazardous Substances Data: 1616809-39-2(Hazardous Substances Data)

Upstream product

• 37098-75-2 2-fluoro-5-chlorosulfonylbenzoic acid 
• 3863-11-4 3,4-difluoroaniline 
• 445-29-4 o-fluoro-benzoic acid 
• 949485-81-8 5-(chlorosulfonyl)-2-fluorobenzoyl chloride 

Downstream Products

• 1616807-58-9 N-(3,4-difluorophenyl)-2-fluoro-5-(N-tert-pentylsulfamoyl)benzamide 
• 1616807-77-2 N-(3,4-difluorophenyl)-5-(N-(1-ethylcyclopropyl)sulfamoyl)-2-fluorobenzamide 
• 1616807-78-3 (R)-5-(N-(1-cyclopropylethyl)sulfamoyl)-N-(3,4-difluorophenyl)-2-fluorobenzamide 
• 1616807-98-7 N-(3,4-difluorophenyl)-2-fluoro-5-(N-(1-(pyrimidin-2-yl)ethyl)sulfamoyl)benzamide 
• 1616807-99-8 N-(3,4-difluorophenyl)-2-fluoro-5-(N-(1-(pyridin-2-yl)ethyl)sulfamoyl)benzamide 
• 1616808-07-1 (S)-5-(N-(1-cyclopropyl-2,2,2-trifluoroethyl)sulfamoyl)-N-(3,4-difluorophenyl)-2-fluorobenzamide 
• 1616809-05-2 (S)-2-(3-((3,4-difluorophenyl)carbamoyl)-4-fluorophenylsulfonamido)propanoic acid 
• 1616808-32-2 5-(N-cyclopropylsulfamoyl)-N-(3,4-difluorophenyl)-2-fluorobenzamide 

Relevant articles and documents

Synthesis of sulfamoylbenzamide derivatives as HBV capsid assembly effector

The synthesis of novel series of sulfamoylbenzamides as HBV capsid assembly effector is reported. The structure was divided into five parts which were independently modified as part of our lead optimization. All synthesized compounds were evaluated for their anti-HBV activity and toxicity in human hepatocytes, lymphocytes and other cells. Additionally, we assessed their effect on HBV cccDNA formation in an HBeAg reporter cell-based assay. Among the 27 compounds reported, several analogs exhibited submicromolar activities and significant reduction of HBeAg secretion. Selected compounds were studied under negative-stain electron microscopy for their ability to disrupt the HBV capsid formation. Structures were modeled into a binding site recently identified in the HBV capsid protein for similar molecules to rationalize the structure-activity relationships for this family of compounds.

NOVEL ANTIVIRAL AGENTS AGAINST HBV INFECTION

The present invention is directed toward novel compounds and novel methods of use of said compounds of the formula (I), useful as nucleocapsid assembly inhibitors for the treatment of viruses, especially but not exclusively, including pregenomic RNA encapsidation inhibitors of HBV for the treatment of Hepatitis B virus (HBV) infection and related conditions. (Formula (I)) Including hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein A, R1, R2, R3, R4, R5, R6, R7, and R8 are defined herein.